News & Updates
Filter by Specialty:
Rosuvastatin on par with atorvastatin in CAD
Rosuvastatin is as effective as atorvastatin for the composite outcome of all-cause death, myocardial infarction (MI), stroke, or any coronary revascularization at 3 years in adults with coronary artery disease (CAD), according to the secondary analysis of the LODESTAR trial.
Rosuvastatin on par with atorvastatin in CAD
06 Nov 2023
Add-on immunotherapy prolongs survival in advanced endometrial cancer
In the treatment of patients with advanced or recurrent endometrial carcinoma, adding the PD-L1 inhibitor atezolizumab to chemotherapy helps lower the risk of progression or death, according to the phase III AtTEnd trial.
Add-on immunotherapy prolongs survival in advanced endometrial cancer
03 Nov 2023
Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).
Enfortumab vedotin-pembrolizumab beats chemo as 1L Tx for bladder cancer
03 Nov 2023
Biomarker-driven therapies superior to standard care in breast cancer
Patients with breast cancer may gain greater therapeutic advantages from biomarker-driven than standard-of-care therapies, suggests a study.
Biomarker-driven therapies superior to standard care in breast cancer
02 Nov 2023
Esketamine outperforms quetiapine in head-to-head depression trial
In patients with treatment-resistant depression, esketamine nasal spray appears to have superior efficacy compared with extended-release quetiapine when used in combination with conventional antidepressants.
